Latest Information Update: 21 Mar 2000
At a glance
- Originator Pfizer
- Class Anti-inflammatories; Antiasthmatics
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 21 Mar 2000 Profile reviewed but no significant changes made
- 22 May 1998 New profile
- 22 May 1998 Discontinued-Preclinical for Asthma in USA (Unknown route)